NovoCure (NVCR) stock is in focus after the company reported topline Phase 3 TRIDENT data showing no statistically significant overall survival benefit from earlier initiation of Tumor Treating Fields in newly diagnosed glioblastoma.

For context, NovoCure’s share price has been volatile, with a 5.39% 7 day share price return and a 37.19% 90 day share price return, but a 1 year total shareholder return that declined 11.99%, suggesting recent momentum contrasts with weaker long term outcomes.

If this kind of binary clinical outcome has you rethinking concentration risk, it may be worth scanning for other healthcare growth stories through our 39 healthcare AI stocks

With NovoCure shares trading at US$15.05, a reported intrinsic discount of 90.58% and a sizeable gap to the current analyst price target, investors are left asking whether there is mispricing here or whether the market is already factoring in future growth.

Most Popular Narrative: 42.3% Undervalued

The most followed narrative on NovoCure values the stock at $26.07 versus the last close at $15.05, framing the current price as a steep discount to that estimate.

Validation of TTFields therapy in multiple new indications, such as pancreatic cancer (PANOVA-3) and brain metastases from non-small cell lung cancer (METIS), positions NovoCure for potential regulatory approvals and large market expansion beginning in 2026, likely driving topline revenue growth as global cancer incidence rises in the aging population.

Curious what kind of revenue climb and profit margin shift would need to play out for NovoCure to back into that fair value? The narrative leans on a specific growth runway, a future profitability swing, and a premium earnings multiple that together carry most of the weight. The details sit in a tight set of assumptions that could change how you see the current discount.

Result: Fair Value of $26.07 (UNDERVALUED)

However, this NovoCure story can change quickly if reimbursement progress stalls or if slow adoption of Tumor Treating Fields continues to keep revenue and losses under pressure.

Next Steps

Given the mix of excitement and concern around NovoCure right now, it makes sense to move quickly, review the numbers yourself, and carefully weigh the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond NovoCure?

If NovoCure has sharpened your focus on risk and reward, broaden your watchlist with other stocks that match clear financial criteria and avoid relying on a single outcome.

• Target potential upside in smaller companies by reviewing 22 elite penny stocks with strong financials that already show stronger financial profiles than many peers.
• Prioritize value by scanning 43 high quality undervalued stocks that combine quality fundamentals with prices that sit below internally assessed worth.
• Protect your downside by filtering for 67 resilient stocks with low risk scores that score well on stability and balance sheet resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.